test

Stephen Scipione

@Adar1 Capital Management, Llc

Latest period2024 - Q3ReportedManaged Assets$614.886MTotal holdings262
Assets growth rate16.09%Assets growth rate (2-Q avg)18.13%Continuous growth in asset value3 quarters

Portfolio positions

This chart displays the top 10 holdings in Adar1 Capital Management, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 262 positions.

Assets under management

The assets under management (AUM) of Adar1 Capital Management, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 3 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 614.886M in assets, with a quarterly growth rate of 16.09% and a 2-quarter average growth rate of 18.13%. The portfolio is managed by Stephen Scipione, and others.

Portfolio holdings

InvestmentPortfolio %Reported Value
CYTK
Cytokinetics Inc
Recent Activity
Increased 8.47%
7.96%
$48.908M
926,282 shares@ $52.81 avg price
PTGX
Protagonist Therapeutics Inc
Recent Activity
Decreased -38.81%
7.19%
$44.158M
981,295 shares@ $45.0 avg price
BBIO
Bridgebio Pharma Inc
Recent Activity
Increased 14.11%
6%
$36.878M
1.448M shares@ $25.46 avg price
BOXX
Ea Series Trust
Recent Activity
Decreased -7.99%
5.73%
$35.226M
323,382 shares@ $108.93 avg price
ROIV
Roivant Sciences Ltd
Recent Activity
Decreased -27.09%
5.68%
$34.914M
3.025M shares@ $11.54 avg price
IMVT
Immunovant Inc
Recent Activity
Increased 139.63%
5.3%
$32.556M
1.142M shares@ $28.52 avg price
RPRX
Royalty Pharma Plc
Recent Activity
Decreased -7.16%
5.05%
$31.025M
1.097M shares@ $28.29 avg price
KROS
Keros Therapeutics Inc
Recent Activity
Decreased -18.86%
4.21%
$25.863M
445,368 shares@ $58.08 avg price
ASND
Ascendis Pharma A S
Recent Activity
Increased 214.86%
3.92%
$24.099M
161,402 shares@ $149.32 avg price
ZURA
Zura Bio Ltd
Recent Activity
New Position
2.49%
$15.309M
3.771M shares@ $4.07 avg price

1-10 of 262